Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 30th 2017

Observational Study Finds Disparity in Screening for Colorectal Cancer

Surabhi Dangi-Garimella, PhD

Being blind, intellectually disabled, or having a spinal cord injury can reduce the probability of a person being screened for colorectal cancer.

March 29th 2017

Guideline Recommendations Purged Unnecessary Imaging in Early-Stage Breast Cancer

Surabhi Dangi-Garimella, PhD

A study published in the journal Cancer has found that the rate of advanced imaging at the time of breast cancer diagnosis reduced during the period between 2008 and 2015 in the state of Michigan.

Melissa Thompson on How Empathy in Cancer Care Can Give Patients Dignity

March 29th 2017

Melissa Thompson on How Empathy in Cancer Care Can Give Patients Dignity

Empathy is the root of dignity for patients, and healthcare providers need to consciously adjust their communication styles to demonstrate that empathy, according to Melissa Thompson, MBA, healthcare strategist, patient, and self-advocate. Some examples include not discussing the patient without including them and using inclusive language that brings the patient and provider together.

March 29th 2017

Radiotherapy Risks Can Outweigh Benefits for Breast Cancer Patients Who Smoke

Christina Mattina

Many women with breast cancer turn to radiotherapy, a proven treatment that reduces the risks of recurrence and death. However, long-term smokers face a greater risk of lung cancer and cardiac mortality from radiotherapy.

March 28th 2017

Analyzing the Near-Term Pipeline for Specialty Drugs

Laura Joszt, MA

The Academy of Managed Care Pharmacy Annual Meeting kicked off on March 28, 2017, in Denver, Colorado, with a look at the specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

March 28th 2017

New PARP Inhibitor, Niraparib, Approved as Maintenance Therapy for Ovarian and Other Cancers

Surabhi Dangi-Garimella, PhD

Results from the randomized NOVA trial convinced the FDA to approve niraparib (Zejula) as maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who are sensitive to platinum-based chemotherapy.

March 27th 2017

Low Socioeconomic Status a Common Thread Among US Smokers

Surabhi Dangi-Garimella, PhD

According to research conducted at the Colorado School of Public Health at CU Anschutz, nearly 75% of smokers have low socioeconomic status.

March 27th 2017

After Surviving Cancer, Young Women at Higher Risk of Adverse Birth Outcomes

Christina Mattina

Women who were diagnosed with cancer at a young age are more likely to experience adverse birth outcomes like preterm birth, low birth weight, and cesarean delivery, particularly if the diagnosis occurred during pregnancy, according to a study in JAMA Oncology.

March 26th 2017

Improving Orphan Drug Incentives to Address Unmet Health Needs

Laura Joszt, MA

While the orphan drug market has been growing, a new study argues that the current unmet needs of patients with rare disease proves that current incentives are not efficiently stimulating orphan drug development.

March 26th 2017

Helping Cancer Patients Quit Smoking Through Counseling and Pharmacotherapy

Christina Mattina

At the 22nd Annual Conference of the National Comprehensive Cancer Network, in Orlando, Florida, Paul M. Cinciripini, PhD, of the University of Texas MD Anderson Cancer Center delivered a presentation on a mission he said he has spent the better part of his life working on: getting patients with cancer to quit smoking cigarettes.

Dr Marianne Fazen Explains How Coverage Decisions Factor Into Cancer Treatment Costs

March 26th 2017

Dr Marianne Fazen Explains How Coverage Decisions Factor Into Cancer Treatment Costs

There are more costs involved in cancer treatment than just the price of the drugs, said Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health. The process of selecting the right treatment also factors into spending, so it is important for patients to get a second opinion.

Dr Shaji Kumar: Advances and Opportunities in Treating Multiple Myeloma

March 25th 2017

Dr Shaji Kumar: Advances and Opportunities in Treating Multiple Myeloma

Despite the abundance of new drugs that have been approved recently and the promising clinical trials of other novel therapies, multiple myeloma remains incurable, explained Shaji Kumar, MD, professor of medicine at the Mayo Clinic. However, he believes that with better options for early intervention and personalized therapies, researchers are on a path to curing the disease.

March 24th 2017

Personalized Care in Lung Cancer Is All About the Molecular Subtype

Surabhi Dangi-Garimella, PhD

At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.

March 24th 2017

Radiation Therapy Updates for Breast Cancer in the NCCN Guidelines

Surabhi Dangi-Garimella, PhD

On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.

Dr Matthew Gubens Highlights Immunotherapy Advances and Combinations for Lung Cancer

March 23rd 2017

Dr Matthew Gubens Highlights Immunotherapy Advances and Combinations for Lung Cancer

Recent research has shown the potential of immunotherapy treatments for treating lung cancer, explained Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco. Dr Gubens also spoke about oncologists’ hopes for using immuno-oncology agents in combination with one another or with chemotherapy.

Dr Moon S. Chen Jr Discusses Strategies for Reducing Cancer Disparities in Asian Americans

March 23rd 2017

Dr Moon S. Chen Jr Discusses Strategies for Reducing Cancer Disparities in Asian Americans

The unique cancer burden among Asian Americans calls for a multifaceted strategy to address these disparities, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities.

March 23rd 2017

Multigene Panels Important for Precision Cancer Care, Variance and Coverage Barriers Remain

Surabhi Dangi-Garimella, PhD

While multigene panels are extremely important in precision cancer care, high levels of variance and insufficient insurance coverage are significant barriers to rapid adoption, according to Kenneth Offit, MD, MPH, from Memorial Sloan Kettering Cancer Center.

March 23rd 2017

FDA Approves First Treatment for Rare Skin Cancer, Merkel Cell Carcinoma

The first treatment for Merkel cell carcinoma, a rare form of skin cancer, has been approved to treat adults and pediatric patients 12 years or older. The drug is also under consideration through Priority Review for treatment of patients with urothelial carcinoma.

March 23rd 2017

Addressing the Roots of Disparities in Cancer Care: Inherent Bias, Resources, and Insurance

Surabhi Dangi-Garimella, PhD

At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, policy researchers with interest in cancer care disparities discussed the source of existing disparities and how they can be successfully addressed.

March 22nd 2017

ASCO's State of Cancer Care in America Report Addresses Access and Affordability Challenges

Surabhi Dangi-Garimella, PhD

The report, which provides an update on all the monumental changes witnessed by the field of oncology over the last year, highlights 3 key achievements: new investments in science and insurance coverage, payment models that emphasize quality, and rapid-learning healthcare systems.

Immunotherapy 2.0: Dr Patricia Salber Interviews Dr Harold Burstein

March 22nd 2017

Immunotherapy 2.0: Dr Patricia Salber Interviews Dr Harold Burstein

The field of immunotherapy is a work in progress and researchers are now expanding the use of this treatment and doing a better job of identifying the patients that will benefit the most from it.

Eliminating Cost Sharing Could Improve Access to Cancer Care, Says Samantha Watson

March 22nd 2017

Eliminating Cost Sharing Could Improve Access to Cancer Care, Says Samantha Watson

If the burden of cost sharing no longer fell on cancer patients, they would be more likely to access care and maintain treatment as prescribed, leading to improved outcomes, according to Samantha Watson, founder and CEO of The Samfund. When faced with high copays, patients are more likely to skip appointments or take only half of their prescribed medications.

March 21st 2017

The Slow Adoption of Precision Radiation Therapy in Prostate Cancer

Surabhi Dangi-Garimella, PhD

Do newer forms of radiation treatments surpass standard radiation in prostate cancer?

March 20th 2017

Biomarker Testing Detects Lung Cancer Recurrence 6 Months Prior to CT Imaging

Christina Mattina

According to a new clinical trial, circulating tumor cells can serve as a biomarker that alerts clinicians to the recurrence of non-small cell lung cancer months before it is detected by CT scans.

David Fabrizio Discusses Challenges of Biomarker-Driven Cancer Treatment

March 20th 2017

David Fabrizio Discusses Challenges of Biomarker-Driven Cancer Treatment

The use of biomarkers in immunotherapy has some technical and biological limitations, and is complicated further by the qualitative aspect of cancer treatment, said David Fabrizio, of Foundation Medicine, Inc. A genomic-based solution could help develop more unified quantitative approaches.

Debra Madden Suggests Oncologists Take a Patient-Centered Approach to Education

March 18th 2017

Debra Madden Suggests Oncologists Take a Patient-Centered Approach to Education

Oncology physicians and nurses need to listen to their patients’ needs and expectations to determine the right way to present information on cancer treatments, including immuno-oncology, according to Debra L. Madden, cancer research advocate and patient representative.

March 17th 2017

5 Things to Look for at NCCN's Annual Conference

Surabhi Dangi-Garimella, PhD

A preview of some of the discussions at the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN).

This Week in Managed Care: March 17, 2017

March 17th 2017

This Week in Managed Care: March 17, 2017

This week, the top managed care stories included the Congressional Budget Office releasing its rating of the GOP's health plan, the Senate voted to confirm Seema Verma for CMS administrator, and Scott Gottlieb, MD, was nominated to lead the FDA.

March 16th 2017

NIH Could See a $6 Billion Funding Cut With New White House Budget

Surabhi Dangi-Garimella, PhD

The White House budget “blueprint” for 2018, which was released today, has recommended substantial cuts to the National Institutes of Health (NIH).

March 16th 2017

Education Can Alleviate Palliative Care Fears Among Patients With Cancer

Christina Mattina

A new study has found that an educational program can help ease worries associated with palliative care, and make cancer patients more likely to use it if referred.

...

81 82 83 84 85 86 87 88 89

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions